3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
2
Sponsor Class
OTHER
10
INDUSTRY
2
OTHER_GOV
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Gastrointestinal
2
Breast
2
Head & Neck
1
Genitourinary
1
CNS
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
31
Carcinoma, Hepatocellular
30
Neoplasms
19
Carcinoma, Renal Cell
16
Melanoma
10
Carcinoma, Non-Small-Cell Lung
10
Thyroid Neoplasms
9
Endometrial Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
6
Colorectal Neoplasms
5
Triple Negative Breast Neoplasms
4
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Liver Neoplasms
4
Carcinoma, Transitional Cell
4
Uterine Cervical Neoplasms
3
Small Cell Lung Carcinoma
3
Recurrence
3
Lymphoma
3
Esophageal Squamous Cell Carcinoma
3
Esophageal Neoplasms
3
Carcinoma
3
Biliary Tract Neoplasms
3
Stomach Neoplasms
2
Solid Tumors
2
Osteosarcoma
2
Lung Neoplasms
2
Kidney Neoplasms
2
Glioma
2
Diabetes Mellitus, Insulin-Dependent, 12
2
Interventions
Capecitabine
77
pembrolizumab
70
Oxaliplatin
68
Cisplatin
56
Fluorouracil
52
Paclitaxel
41
Trastuzumab
37
Nivolumab
35
Leucovorin
27
Docetaxel
27
Irinotecan
22
Ramucirumab
20
Gemcitabine
15
Bevacizumab
15
S 1 (combination)
14
Carboplatin
13
atezolizumab
12
apatinib
12
fludarabine
11
Cyclophosphamide
11
tislelizumab
10
Drug Therapy
10
Injections
8
130-nm albumin-bound paclitaxel
8
trastuzumab deruxtecan
7
durvalumab
7
Ipilimumab
7
Folfox protocol
7
Albumin-Bound Paclitaxel
7
titanium silicide
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Stomach Neoplasms
×
lenvatinib
×
Clear all
NCT03797326
2026-05-04
LEAP-005
Merck Sharp & Dohme LLC
Phase 2
Completed
611 enrolled
27 charts
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled